On September 8, 2022 Oxford Vacmedix reported the OVM-200 Phase 1 Clinical Trial at The Christie in Manchester was featured on ITV’s Granada News on Wednesday 7th September 2022 (Press release, Oxford Vacmedix, SEP 8, 2022, View Source;utm_medium=rss&utm_campaign=ovm-200-clinical-trial-featured-on-tv [SID1234619257]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

It is a first-in-class of ROP cancer vaccine in human clinical trial. ROP therapeutic vaccines will provide additional options for the treatment of cancer patients.

Professor Shisong Jiang, Chief Scientific Officer and Founder of OVM said:

We see the potential benefits of a vaccination approach both in stimulating the body’s immune system to attack the cancer and also, in future trials, enhancing the efficacy of other immune-oncology agents. This Phase I trial is a first step towards having effective cancer vaccines.